Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

PLK1

2 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology · Bioinfo & AI

Biallelic loss of RB1 in hepatocellular carcinoma as synthetic lethal target for artificial intelligence-guided therapy

An J, Kim W, Zhang X, et al.

Signal transduction and targeted therapy

This study characterized biallelic inactivation of the RB1 tumor suppressor gene (RB1-Bi) in hepatocellular carcinoma (HCC), finding it in 14.6% of patients and associating it with significantly reduced overall survival. A deep learning model (FR-MIL) was developed to accurately predict RB1-Bi status from routine histopathology slides. High-throughput drug screenings revealed that RB1-Bi HCC cells are particularly sensitive to inhibitors targeting mitotic regulators and PARP inhibitors. These synthetic lethal interactions were validated in vitro and in vivo, suggesting RB1-Bi is an actionable biomarker for precision medicine in HCC.

Clinical · Molecular biology

A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcoma

Huang J, Liu X, Floyd W, et al.

JCI insight

An in vivo CRISPR screen identified BAP1 as a potent tumor suppressor in undifferentiated pleomorphic sarcomas (UPS). BAP1-deficient sarcomas exhibit a markedly immunosuppressive tumor microenvironment. Researchers found that PLK1 is required for the growth and survival of these sarcomas, with elevated expression in human UPS where BAP1 is reduced. Pharmacologic inhibition of PLK1 with volasertib significantly suppressed tumor growth in mouse models. Furthermore, combining PLK1 inhibition with anti-PD-1 therapy enhanced tumor control and improved survival.